OBJECTIVE: To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction. DESIGN: Prospective, double blind placebo controlled trial. SETTING: Medicine for the elderly day hospital. PATIENTS: 66 patients (average age 81) with left ventricular systolic dysfunction identified by echocardiography. INTERVENTIONS: 10 weeks of treatment with titrated doses of perindopril or placebo. MAIN OUTCOME MEASURES: Six minute walking distance 10 weeks following treatment, quality of life measurements including the Minnesota living with heart failure questionnaire and the 36 item short form health survey. RESULTS: In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p < 0.001). The medication was well tolerated and there were no significant adverse events. CONCLUSIONS: Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.
RCT Entities:
OBJECTIVE: To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction. DESIGN: Prospective, double blind placebo controlled trial. SETTING: Medicine for the elderly day hospital. PATIENTS: 66 patients (average age 81) with left ventricular systolic dysfunction identified by echocardiography. INTERVENTIONS: 10 weeks of treatment with titrated doses of perindopril or placebo. MAIN OUTCOME MEASURES: Six minute walking distance 10 weeks following treatment, quality of life measurements including the Minnesota living with heart failure questionnaire and the 36 item short form health survey. RESULTS: In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p < 0.001). The medication was well tolerated and there were no significant adverse events. CONCLUSIONS: Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.
Authors: J G Cleland; M Tendera; J Adamus; N Freemantle; C S Gray; M Lye; D O'Mahony; L Polonski; J Taylor Journal: Eur J Heart Fail Date: 1999-08 Impact factor: 15.534
Authors: M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald Journal: Lancet Date: 2000-05-06 Impact factor: 79.321
Authors: G H Guyatt; M J Sullivan; P J Thompson; E L Fallen; S O Pugsley; D W Taylor; L B Berman Journal: Can Med Assoc J Date: 1985-04-15 Impact factor: 8.262
Authors: Thomas W Buford; Todd M Manini; Fang-Chi Hsu; Matteo Cesari; Stephen D Anton; Susan Nayfield; Randall S Stafford; Timothy S Church; Marco Pahor; Christy S Carter Journal: J Am Geriatr Soc Date: 2012-06-21 Impact factor: 5.562
Authors: Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor Journal: Ageing Res Rev Date: 2015-10-14 Impact factor: 10.895
Authors: L D Carbone; S Vasan; R L Prentice; G Harshfield; B Haring; J A Cauley; K C Johnson Journal: Osteoporos Int Date: 2019-06-17 Impact factor: 4.507